- BNF:
- 2.8.2
- Status:
- Grey - after consultant/specialist initiation, Red, Green, Green - after consultant/specialist initiation
- Decision Date:
- None
Comments
RED:1,5 NICE TA170:
prevention of VTE after hip or knee replacement in adults
GREEN: NICE TA256:
anticoagulant option in AF patients as per local guidance (decision date -
July 2012)
GREEN (following
specialist initiation): for the following indications as per
SPC:
- NICE TA261: Venous
thromboembolism (treatment and long-term secondary prevention).
Rivaroxaban - a recommended option for treating DVT, and to help prevent a
pulmonary embolism or another DVT. (Decision date - March 2013)
- NICE TA287: for treating
pulmonary embolism and preventing recurrent venous thromboembolism
(decision date - August 2013)
- 2.5mg preparation. NICE TA335: GREEN
specialist initiation for patients commenced on rivaroxaban 2.5mg tablet,
with a specified 12 month stop date. Indicated as per NICE
TA335: preventing adverse outcomes after acute management of acute
coronary syndrome. (Decision date May 2015, further
decision – August 2023)
GREY 3,6 after
consultant/specialist initiation: NICE TA607: Rivaroxaban
2.5mg + aspirin for the prevention of atherothrombotic events in people with
coronary or peripheral artery disease. Treatment should only be started after
an informed discussion with the patient about the risks and benefits of
treatment. (Decision date - November 2019)
Grey Drug Classifications
- 3: Known excess of significant adverse events compared with standard therapy
- 6: NICE guidance
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 5: Is new to clinical practice and unfamiliar, necessitating a period of accumulation of experience, firstly (and most rapidly) by consultants/specialists
search again
